Examining the TMEM230 gene's role in atherosclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on understanding the modulation of the TMEM230 gene in patients with vascular pathologies, particularly atherosclerosis. It involves collecting and analyzing approximately 12 samples of vascular tissue from surgical procedures, alongside venous blood samples. The study aims to uncover the molecular mechanisms of atherosclerosis by examining genetic factors and their interactions with various risk factors. The findings could provide insights into the underlying causes of atherosclerosis and potential therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult patients (age \> 18 years)
* consent to participate in the study,
* patients coming to the Vascular Surgery Unit I of the IRCCS Policlinico San Donato for a vascular pathology of the arterial or venous district worthy of surgical treatment.

Exclusion Criteria:

* minor patients,
* patients who have not given their consent to participate in the study,
* patients who have vascular pathologies of the arterial or venous district not susceptible to surgical intervention.

Where it's running

• I.R.C.C.S. Policlinico San Donato
  San Donato Milanese, Milan, Italy Recruiting

Study contacts

• Study coordinator: Mattia Ricotti
• Email: mattia.ricotti@grupposandonato.it
• Phone: +390252774236

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Cilostazol and Aspirin to Prevent Heart and Brain Events in Type 2 Diabetes

  In people with type 2 diabetes and higher cardiovascular risk, researchers are testing whether taking cilostazol plus aspirin can help reduce major heart and brain events.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07719894

• Dapagliflozin to slow coronary plaque progression in type 2 diabetes

  This trial tests whether adding dapagliflozin to standard care can slow or reverse coronary plaque buildup in adults with type 2 diabetes and stable coronary disease.

  Recruiting at 2 sites Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07614230

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.